Combinatorial chemoprevention of intestinal neoplasia
Top Cited Papers
- 1 September 2000
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 6 (9) , 1024-1028
- https://doi.org/10.1038/79534
Abstract
A combination of two drugs afforded remarkable protection from intestinal neoplasia in APCMin/+ mice, a murine model of human familial adenomatous polyposis (FAP). One of the drugs was sulindac, a prototypical non-steroidal anti-inflammatory drug with established chemopreventative activity. The second drug was EKI-569, a newly developed, irreversible inhibitor of the epidermal growth factor receptor kinase. Although 100% of the untreated APCMin/+ mice developed ∼ 20 polyps, nearly half the mice treated with these two agents developed no polyps at all. These results suggest a powerful strategy for the chemoprevention of human colonic neoplasia.Keywords
This publication has 35 references indexed in Scilit:
- Multiagent chemopreventive agent combinationsJournal of Cellular Biochemistry, 2000
- Chemoprevention in hereditary colorectal cancer syndromesCancer, 1999
- CHEMOPREVENTION OF BREAST CANCERSurgical Clinics of North America, 1999
- Retinoids in lung cancer chemoprevention and treatmentAnnals of Oncology, 1999
- Biochemoprevention for Dysplastic Lesions of the Upper Aerodigestive TractJAMA Otolaryngology–Head & Neck Surgery, 1999
- The biology and treatment of acute progranulocytic leukemiaCurrent Opinion in Oncology, 1999
- Treatment and Prevention of Multidrug-Resistant TuberculosisDrugs, 1999
- Recent Advances in Chemoprevention of CancerScience, 1997
- Lessons from Hereditary Colorectal CancerCell, 1996
- NSAID-INDUCED POLYP REGRESSION IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTSGastroenterology Clinics of North America, 1996